Voloridge Investment Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Voloridge Investment Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-175,537	Closed	-$2.66M	–	1385
2023 Q4	$2.66M	Buy	+175,537	New	+$2.56M	0.01%	762
2023 Q2	–	Sell	-147,923	Closed	-$2.54M	–	1605
2023 Q1	$2.54M	Buy	147,923 +1,894	+1%	+$38.4K	0.01%	911
2022 Q4	$2.94M	Sell	146,029 -63,405	-30%	-$1.36M	0.02%	857
2022 Q3	$4.54M	Sell	209,434 -70,076	-25%	-$1.92M	0.02%	685
2022 Q2	$7.85M	Buy	279,510 +147,570	+112%	+$3.91M	0.04%	529
2022 Q1	$6.09M	Buy	131,940 +47,028	+55%	+$2.54M	0.03%	568
2021 Q4	$7.14M	Buy	84,912 +37,590	+79%	+$2.91M	0.04%	574
2021 Q3	$3.15M	Buy	47,322 +20,208	+75%	+$1.17M	0.02%	871
2021 Q2	$1.44M	Buy	+27,114	New	+$1.45M	0.01%	1124

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Voloridge Investment Management's ZNTL Position: Q1 2024 in Review

Voloridge Investment Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2024, closing a stake of 175,537 shares — an estimated $2.66M sold.

Voloridge Investment Management first reported a position in ZNTL in Q2 2021 and held it in 9 quarters. The position peaked at $7.85M in Q2 2022. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

Voloridge Investment Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Voloridge Investment Management sold 175,537 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $2.66M.
Voloridge Investment Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Voloridge Investment Management's Zentalis Pharmaceuticals position peaked at $7.85M in Q2 2022.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Voloridge Investment Management's 13F filing for Q1 2024, filed 15 May 2024.